What is DARA Biosciences Retained Earnings?
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. DARA Biosciences's retained earnings for the quarter that ended in Sep. 2015 was $-74.53 Mil.
DARA Biosciences's quarterly retained earnings
declined
from Mar. 2015 ($-69.15 Mil) to Jun. 2015 ($-71.83 Mil) and
declined
from Jun. 2015 ($-71.83 Mil) to Sep. 2015 ($-74.53 Mil).
DARA Biosciences's annual retained earnings
declined
from Dec. 2012 ($-47.03 Mil) to Dec. 2013 ($-56.99 Mil) and
declined
from Dec. 2013 ($-56.99 Mil) to Dec. 2014 ($-65.99 Mil).
DARA Biosciences Retained Earnings Calculation
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
DARA Biosciences (NAS:DARA) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
DARA Biosciences (DARA Biosciences) Business Description
Traded in Other Exchanges
N/A
Address
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
Executives
| David Drutz |
director, officer: Executive Chairman and CMO |
8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
| David L. Tousley |
officer: CFO |
14610 PAWNEE LANE, LEAWOOD KS 66224 |
| Gail Lieberman |
director |
175 EAST 79TH STREET, APT. 4D, NEW YORK NY 10075 |
| Paul John Richardson |
director |
17 COUNTRY OAKS ROAD, LEBANON NJ 08833 |
| Steve Gorlin |
director |
150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541 |
| Ann A Rosar |
officer: Vice President Finance |
C/O 801 CAPITOLA DRIVE, DURHAM NC 27713 |
| John C Thomas |
director |
8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
| Geert Cauwenbergh |
director |
1 STULTS DRIVE, PLAINSBORO NJ 08536 |
| Kurt M Eichler |
director |
C/O SPRING BANK PHARMACEUTICALS, INC., STE S-7, MILFORD MA 01757 |
| Hamilton Jordan |
director |
|
| Stuart C Mcwhorter |
director |
113 SEABOARD LANE, FRANKLIN TN 37067 |
| Timothy J Barberich |
director |
40 ELM ST, CONCORD MA 01752 |
| Michael P Duffy |
officer: SVP, GC and Secretary |
C/O POINT THERAPEUTICS INC, 125 SUMMER STREET SUITE 1840, BOSTON MA 02110 |
| Richard J Benjamin |
director |
15 WHITE PINE ROAD, NEWTON MA 02464 |
| Larry G Pickering |
director |
26130 MANDEVILLA DRIVE, BONITA SPRINGS FL 34134 |
DARA Biosciences (DARA Biosciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DARA has been successfully added to your 